Genexine, Inc.

Equities

A095700

KR7095700001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
7,280 ^KRW	-0.95%		+3.41%	-26.46%

2023	Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	CI

Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 15, 2023 at 03:27 am EDT

Genexine, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 7 million compared to KRW 1.96 million a year ago. Net loss was KRW 23,913.79 million compared to net income of KRW 16,399.4 million a year ago.

Basic loss per share from continuing operations was KRW 625 compared to basic earnings per share from continuing operations of KRW 503.8462 a year ago. Diluted loss per share from continuing operations was KRW 665 compared to diluted earnings per share from continuing operations of KRW 503.8462 a year ago. Basic loss per share was KRW 625 compared to basic earnings per share of KRW 655 a year ago.

Diluted loss per share was KRW 665.

Latest news about Genexine, Inc.

Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Genexine, Inc. and PT Kalbe Genexine Biologics Receives the First Market Approval for Novel Long-Acting Erythropoietin, Efepoetin Alfa, from the Indonesian Food and Drug Authority	23-10-23	CI
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	23-08-31	MT
Sector Update: Health Care	23-08-31	MT
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	23-08-31	MT
I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says	23-08-31	MT
Genexine Announces Positive Topline Results from the Multi-Center, Randomized, Open-Label, Active-Controlled Pivotal Phase 3 Study	23-08-30	CI
Henlius Biotech Grants Hansizhuang License to Kalbe Genexine Biologics	23-08-28	MT
Genexine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Genexine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Genexine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
Genexine Receives Fast Track Designation from Korean Health Authority for Its Promising DNA Vaccine for Advanced Cervical Cancer	23-01-20	CI
Genexine, Inc. to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference	23-01-08	CI
Genexine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Genexine to Raise $70 Million via Share Issuance	22-09-26	MT
Genexine’s Announces that DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer	22-09-07	CI
Genexine to Present Phase 2 Study of GX-188E in Combination with KEYTRUDA® (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology Congress 2022	22-08-25	CI
Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma	22-08-17	CI
I-Mab Completes Enrollment in China Phase 3 Trial of Eftansomatropin Alfa in Pediatric Growth Hormone Deficiency	22-06-14	MT
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)	22-06-14	CI
Genexine Reports Encouraging Top-Line Results of the Phase 1B/2 Clinical Trial with GX-I7 (Efineptakin Alfa) in Refractory or Recurrent (R/R) Metastatic Triple Negative Breast Cancer	22-06-07	CI
Genexine Appoints Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation	22-05-24	CI
Y-Biologics Inc. announced that it expects to receive KRW 30 billion in funding from a group of investors	22-02-23	CI
Indonesia in talks with WHO to become global vaccine hub: minister	21-09-15	RE
Genexine : South Korea's Genexine signs COVID-19 vaccine candidate manufacturing deal with Hanmi	21-05-17	RE

Chart Genexine, Inc.

Duration

Period

More charts

Company Profile

Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENEXINE, INC.	-26.46%	219M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs